Friedrich Graf Finckenstein - 03 Jan 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Medical Officer
Signature
/s/ Friedrich Graf Finckenstein
Issuer symbol
IOVA
Transactions as of
03 Jan 2023
Net transactions value
-$67,351
Form type
4
Filing time
05 Jan 2023, 19:57:15 UTC
Previous filing
16 Jun 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +19,690 +153% $0.000000 32,571 03 Jan 2023 Direct F1
transaction IOVA Common Stock Tax liability $67,351 -11,023 -34% $6.11 21,548 03 Jan 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -19,690 -100% $0.000000* 0 03 Jan 2023 Common stock 19,690 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021.
F2 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
F3 Represents the common stock remaining after deducting the common stock withheld for taxes.
F4 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5 As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023.